- Home
- / Infant Bacterial Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Infant Bacterial Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | 312.0K | 94.0K | 12.0K | 77.0K | 4.0K | |||
| Operating expense total | 38.6M | 46.4M | 71.4M | 43.9M | 65.0M | 133.9M | 144.5M | 68.2M |
| Depreciation and amortization | 816.0K | 816.0K | 816.0K | 816.0K | 816.0K | 816.0K | 816.0K | 816.0K |
| EBITDA | (38.6M) | (46.4M) | (71.1M) | (43.8M) | (65.0M) | (133.8M) | (144.5M) | (68.2M) |
| EBIT | (39.4M) | (47.2M) | (71.9M) | (44.6M) | (65.8M) | (134.6M) | (145.3M) | (69.0M) |
| Interest income | 327.0K | 1.6M | 214.0K | 650.0K | 11.5M | 8.4M | 3.8M | |
| Interest expense | 1.5M | 725.0K | 303.0K | 413.0K | 293.0K | |||
| Pre tax profit | (40.6M) | (46.3M) | (72.0M) | (45.0M) | (65.5M) | (123.1M) | (136.9M) | (65.2M) |
| Net Income | (40.6M) | (46.3M) | (72.0M) | (45.0M) | (65.5M) | (123.1M) | (136.9M) | (65.2M) |